Clinical Trials

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)


Study ID
Merck MK-3475-495

NCT Number
NCT03516981 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0314

Principle Investigator
Dr. Martin Gutierrez

Phase
II

Sponsor
Merck Sharp & Dohme Corp.


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now